Literature DB >> 10884021

Is nuclear factor-kappaB a good treatment target in brain ischemia/reperfusion injury?

J E Carroll1, D C Hess, E F Howard, W D Hill.   

Abstract

Nuclear factor-kappaB (NF-kappaB) is a transcription factor which resides in its unactivated form in the cytoplasm. Following activation subsequent to cerebral ischemia and reperfusion injury, NF-kappaB acts on genes for cytokines, adhesion molecules, nitric oxide synthase, cyclooxygenase-2, metalloproteinase-9, and perhaps apoptotic genes. These genes have a variety of positive and negative influences on the outcome of brain injury. The effect of manipulation of NF-kappaB needs to be examined critically, as it pertains to these reactive genes.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10884021

Source DB:  PubMed          Journal:  Neuroreport        ISSN: 0959-4965            Impact factor:   1.837


  10 in total

1.  The treatment of traumatic brain injury with velcade.

Authors:  Changsheng Qu; Asim Mahmood; Ruizhuo Ning; Ye Xiong; Li Zhang; Jieli Chen; Hao Jiang; Michael Chopp
Journal:  J Neurotrauma       Date:  2010-09       Impact factor: 5.269

2.  Inflammation and NFkappaB activation is decreased by hypothermia following global cerebral ischemia.

Authors:  Carla M Webster; Stephen Kelly; Maya A Koike; Valerie Y Chock; Rona G Giffard; Midori A Yenari
Journal:  Neurobiol Dis       Date:  2008-11-19       Impact factor: 5.996

3.  Longitudinal assessment of imatinib's effect on the blood-brain barrier after ischemia/reperfusion injury with permeability MRI.

Authors:  Zamir Merali; Jackie Leung; D Mikulis; F Silver; Andrea Kassner
Journal:  Transl Stroke Res       Date:  2014-08-23       Impact factor: 6.829

Review 4.  Proteasome inhibition: a new anti-inflammatory strategy.

Authors:  Peter J Elliott; Thomas Matthias Zollner; Wolf-Henning Boehncke
Journal:  J Mol Med (Berl)       Date:  2003-03-26       Impact factor: 4.599

5.  Ischemic preconditioning mediates cyclooxygenase-2 expression via nuclear factor-kappa B activation in mixed cortical neuronal cultures.

Authors:  Eun Joo Kim; Ami P Raval; Nina Hirsch; Miguel A Perez-Pinzon
Journal:  Transl Stroke Res       Date:  2010-01-26       Impact factor: 6.829

6.  N-acetylcysteine in severe falciparum malaria in Thailand.

Authors:  Sombat Treeprasertsuk; Srivicha Krudsood; Thanawat Tosukhowong; Wirach Maek-A-Nantawat; Suparp Vannaphan; Tosaporn Saengnetswang; Sornchai Looareesuwan; Walter F Kuhn; Gary Brittenham; James Carroll
Journal:  Southeast Asian J Trop Med Public Health       Date:  2003-03       Impact factor: 0.267

7.  Peripheral inflammation preceeding ischemia impairs neuronal survival through mechanisms involving miR-127 in aged animals.

Authors:  Sanna Loppi; Paula Korhonen; Maria Bouvy-Liivrand; Simone Caligola; Tiia A Turunen; Mikko P Turunen; Ana Hernandez de Sande; Natalia Kołosowska; Flavia Scoyni; Anna Rosell; Teresa García-Berrocoso; Sighild Lemarchant; Hiramani Dhungana; Joan Montaner; Jari Koistinaho; Katja M Kanninen; Minna U Kaikkonen; Rosalba Giugno; Merja Heinäniemi; Tarja Malm
Journal:  Aging Cell       Date:  2020-12-28       Impact factor: 11.005

8.  A Systematic, Integrated Study on the Neuroprotective Effects of Hydroxysafflor Yellow A Revealed by (1)H NMR-Based Metabonomics and the NF-κB Pathway.

Authors:  Yuanyan Liu; Zeqin Lian; Haibo Zhu; Yinghong Wang; Shishan Yu; Tingting Chen; Jing Qu; Jianbei Li; Shuanggang Ma; Xianhong Chen
Journal:  Evid Based Complement Alternat Med       Date:  2013-04-22       Impact factor: 2.629

9.  Using a novel in vivo model to study the function of nuclear factor kappa B in cerebral ischemic injury.

Authors:  Rui Wang; Songlan Liang; Hui Yue; Lijie Chen
Journal:  Med Sci Monit       Date:  2012-11

10.  Neuroproteome changes after ischemia/reperfusion injury and tissue plasminogen activator administration in rats: a quantitative iTRAQ proteomics study.

Authors:  Zamir Merali; Meah MingYang Gao; Tim Bowes; Jian Chen; Kenneth Evans; Andrea Kassner
Journal:  PLoS One       Date:  2014-05-30       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.